에피제네틱스 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2024-2030년)

Epigenetics Market Growth & Trends:

The global epigenetics market size is expected to reach USD 39.15 billion by 2030, registering a CAGR of 15.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is being driven by factors, such as the rise in funding, investment & regulatory approvals for epigenetics research & development, the expansion of the use of epigenetic enzymes in drug discovery & development, and the decreasing cost of genome sequencing. Since epigenetics has demonstrated beneficial applications outside of cancer, commercial expansion is envisaged.The rising demand for understanding epigenetic alterations at the molecular level, as well as the advancement of medicinal treatments, would likely push these organizations to support research and development programs.

Furthermore, initiatives, such as the Epidemiology and Genomics Research Program (EGRP), provide incentives for research efforts aimed at better-comprehending cancer genesis and consequences.A few organizations that help fuel the market's rise are the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institutes of Health (NIH). These organizations support funding and help for initiatives involving product development and R&D in the field of epigenetics. For instance, the National Institutes of Health aggressively promotes cutting-edge epigenetic research worldwide through its common fund epigenomics program.

Epigenetics Market Report Highlights:

• By product, the reagents segment dominated the industry, accounting for 33.45% of the global revenue in 2023. The large share of this segment can be attributed to the high usage of reagents in epigenetic research studies.
• By technology, the DNA methylation segment dominated the market with a revenue share of 45.36% in 2023. DNA methylation's demand in epigenetics stems from its pivotal role in gene expression regulation.
• By application, the oncology segment dominated the market with a revenue share of 69.06% in 2023. Oncology's demand for epigenetics arises from the intricate relationship between epigenetic alterations and cancer development.
• North America dominated the market and accounted for a 38.19% share in 2023. The region experiences growth due to heightened public awareness, robust medical facilities, and substantial R&D investments.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Technology
  • 1.2.3. Application
  • 1.2.4. End-use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives
  • 1.10.1. Objective - 1
  • 1.10.2. Objective - 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Insights Landscape

Chapter 3. Epigenetics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cancer
    • 3.2.1.2. Rising geriatric patient population
    • 3.2.1.3. Increasing government initiatives
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of standardization in epigenetics-based diagnostics
    • 3.2.2.2. Lack of skilled professionals
  • 3.2.3. Market opportunity analysis
    • 3.2.3.1. Improving healthcare infrastructure in developing economies
• 3.3. Epigenetics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Epigenetics Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Epigenetics Market Product Movement Analysis
• 4.3. Global Epigenetics Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. Reagents
  • 4.4.1. Reagents market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Kits
  • 4.5.1. Kits market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. ChIP sequencing Kit
    • 4.5.2.1. ChIP sequencing kit market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Whole Genomic Amplification Kit
    • 4.5.3.1. Whole genomic amplification kit market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.4. Bisulfite Conversion Kit
    • 4.5.4.1. Bisulfite conversion kit market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.5. RNA sequencing Kit
    • 4.5.5.1. RNA sequencing kit market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.6. Others
    • 4.5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Instruments
  • 4.6.1. Instruments market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Enzymes
  • 4.7.1. Enzymes market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Services
  • 4.8.1. Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Epigenetics Market: Technology Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Epigenetics Market Technology Movement Analysis
• 5.3. Global Epigenetics Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 5.4. DNA Methylation
  • 5.4.1. DNA methylation market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Histone Methylation
  • 5.5.1. Histone methylation market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Histone Acetylation
  • 5.6.1. Histone Acetylation Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Large non-coding RNA
  • 5.7.1. Large non-coding RNA market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. MicroRNA modification
  • 5.8.1. MicroRNA modification market estimates and forecasts 2018 to 2030 (USD Million)
• 5.9. Chromatin structures
  • 5.9.1. Chromatin structures market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Epigenetics Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Epigenetics Market Application Movement Analysis
• 6.3. Global Epigenetics Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 6.4. Oncology
  • 6.4.1. Oncology market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Solid tumors
    • 6.4.2.1. Solid tumors market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Liquid tumors
    • 6.4.3.1. Liquid tumors market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Non-oncology
  • 6.5.1. Non-oncology Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Inflammatory diseases
    • 6.5.2.1. Inflammatory diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Metabolic diseases
    • 6.5.3.1. Metabolic diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Infectious diseases
    • 6.5.4.1. Infectious diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Cardiovascular diseases
    • 6.5.5.1. Cardiovascular diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Others
    • 6.5.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Epigenetics Market: End-use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Global Epigenetics Market End-use Movement Analysis
• 7.3. Global Epigenetics Market Size & Trend Analysis, by End-use, 2018 to 2030 (USD Million)
• 7.4. Academic Research
  • 7.4.1. Academic research market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Clinical Research
  • 7.5.1. Clinical research market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Hospitals & Clinics
  • 7.6.1. Hospitals & clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Pharmaceutical & Biotechnology Companies
  • 7.7.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Other Users
  • 7.8.1. Other users market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Epigenetics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2023 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 8.4. North America
  • 8.4.1. North America market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework
    • 8.4.2.3. Target disease prevalence
    • 8.4.2.4. Competitive scenario
    • 8.4.2.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework
    • 8.4.3.3. Target disease prevalence
    • 8.4.3.4. Competitive scenario
    • 8.4.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework
    • 8.5.2.3. Target disease prevalence
    • 8.5.2.4. Competitive scenario
    • 8.5.2.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework
    • 8.5.3.3. Target disease prevalence
    • 8.5.3.4. Competitive scenario
    • 8.5.3.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework
    • 8.5.4.3. Target disease prevalence
    • 8.5.4.4. Competitive scenario
    • 8.5.4.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework
    • 8.5.5.3. Target disease prevalence
    • 8.5.5.4. Competitive scenario
    • 8.5.5.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework
    • 8.5.6.3. Target disease prevalence
    • 8.5.6.4. Competitive scenario
    • 8.5.6.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.7. Norway
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework
    • 8.5.7.3. Target disease prevalence
    • 8.5.7.4. Competitive scenario
    • 8.5.7.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Target disease prevalence
    • 8.5.8.3. Regulatory framework
    • 8.5.8.4. Competitive scenario
    • 8.5.8.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.9. Denmark
    • 8.5.9.1. Key country dynamics
    • 8.5.9.2. Regulatory framework
    • 8.5.9.3. Target disease prevalence
    • 8.5.9.4. Competitive scenario
    • 8.5.9.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework
    • 8.6.2.3. Target disease prevalence
    • 8.6.2.4. Competitive scenario
    • 8.6.2.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework
    • 8.6.3.3. Target disease prevalence
    • 8.6.3.4. Competitive scenario
    • 8.6.3.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Target disease prevalence
    • 8.6.4.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework
    • 8.6.5.3. Target disease prevalence
    • 8.6.5.4. Competitive scenario
    • 8.6.5.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework
    • 8.6.6.3. Target disease prevalence
    • 8.6.6.4. Competitive scenario
    • 8.6.6.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key country dynamics
    • 8.6.7.2. Target disease prevalence
    • 8.6.7.3. Regulatory framework
    • 8.6.7.4. Competitive scenario
    • 8.6.7.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework
    • 8.7.2.3. Target disease prevalence
    • 8.7.2.4. Competitive scenario
    • 8.7.2.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. Mexico
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework
    • 8.7.3.3. Target disease prevalence
    • 8.7.3.4. Competitive scenario
    • 8.7.3.5. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Argentina
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework
    • 8.7.4.3. Target disease prevalence
    • 8.7.4.4. Competitive scenario
    • 8.7.4.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key country dynamics
    • 8.8.2.2. Regulatory framework
    • 8.8.2.3. Competitive scenario
    • 8.8.2.4. Target disease prevalence
    • 8.8.2.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key country dynamics
    • 8.8.3.2. Regulatory framework
    • 8.8.3.3. Target disease prevalence
    • 8.8.3.4. Competitive scenario
    • 8.8.3.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key country dynamics
    • 8.8.4.2. Regulatory framework
    • 8.8.4.3. Target disease prevalence
    • 8.8.4.4. Competitive scenario
    • 8.8.4.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key country dynamics
    • 8.8.5.2. Regulatory framework
    • 8.8.5.3. Target disease prevalence
    • 8.8.5.4. Competitive scenario
    • 8.8.5.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2023
• 9.4. Company Profiles/Listing
  • 9.4.1. F. Hoffmann-La Roche Ltd
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Thermo Fisher Scientific Inc.
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Eisai Co., Ltd.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Novartis AG
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. ELEMENT BIOSCIENCES.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Dovetail Genomics.
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Illumina, Inc.
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Promega Corporation
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Abcam plc
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives